Avatar

The Future of CAR T Therapies in Myeloma in 2018

By Nina Shah 4 Videos
June 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
UChicago Medicine Comprehensive Cancer Center

UChicago Annual Updates from ASH 2019

Fri, Feb 28, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussi...

Feat. M. Leukam
23:48
UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Res...

Feat. J. Jasielec
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
27:06
UChicago CAR T-Cell Symposium 2019

Why Does CAR T-Cell Therapy Fail? An Update on Mechanisms of Resistance/...

Feat. J. Kline
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

07:23
Indy Hematology Review

Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR T cells

Feat. K. Anderson
17:44
UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytokine ...

Feat. S. Kosuri
06:41
UChicago CAR T-Cell Symposium 2019

Mechanisms of Acquired CAR-T Cell Resistance: Is There a 'Best' in Produ...

Feat. J. Labelle
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma